Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
LABORATORIO REIG JOFRE ( (ES:RJF) ) just unveiled an announcement.
Laboratorio Reig Jofre, S.A. has outlined its remuneration policy for directors for the years 2023 to 2025, which was approved by the General Meeting of Shareholders. The policy includes fixed and periodic remuneration, as well as compensation for expenses related to board activities. The remuneration policy does not involve external advisors and is internally developed, ensuring compliance with relevant regulations. This announcement highlights the company’s structured approach to director remuneration, potentially impacting stakeholder perceptions and aligning with industry standards.
More about LABORATORIO REIG JOFRE
Laboratorio Reig Jofre, S.A. operates in the pharmaceutical industry, focusing on the development, production, and marketing of pharmaceutical products. The company is based in Barcelona and is committed to innovation and sustainability in its operations.
YTD Price Performance: 0.79%
Average Trading Volume: 466
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €216.1M
See more insights into RJF stock on TipRanks’ Stock Analysis page.